Portfolio

Top Stocks

Quarterly Top 10 Holdings for Quarter End 31-Mar-2020

as of 31-Mar-2020

Microsoft Corporation 12.94%
Teladoc Health Inc. 12.72%
Scotts Miracle-Gro Comapny (The) 7.99%
GW Pharmaceuticals Plc 7.33%
Abbott Laboratories 7.17%
Vestas Wind Systems A/S ADR 6.69%
Merck & Company Inc. 5.72%
AbbVie Inc. 5.15%
Corbus Pharmaceuticals Holdings Inc. 4.96%
Cara Therapeutics Inc. 4.81%

Top Portfolio Holdings for Quarter End 31-Mar-2020

as of 31-Mar-2020

1. Microsoft Corp (MSFT)
Microsoft is developing a new product in Microsoft's cloud computing business that is meant to help states that have legalized the medical or recreational use of marijuana. The software is meant to keep tabs on sales and commerce, ensuring that they remain in the daylight of legality.
2. Teladoc Health Inc. (TDOC)
Is a telehealth platform that delivers 24-hour, on-demand healthcare via mobile devices, the Internet, video, and phone. Its platform connects members with a network of physicians and behavioral health professionals.
3. Scotts Miracle-Gro Company (SMG)
Hydroponics is the process of growing plants in liquids without the use of soil and is a popular method for cultivating marijuana.
4. GW Pharmaceuticals PLC (GWPH)
GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant.
5. Abbott Laboratories (ABT)
Manufactures Dexanabinol: A synthetic cannabinoid that protects the brain from damage (cardiac surgery), regain memory and other high-level functions following traumatic brain injury. Possible future use as an anti-cancer drug.
6. Vestas Wind Systems A/S ADR (VWDRY)
Vestas Wind Systems is one of the largest manufacturers of wind turbines in the world
7. Merck & Company Inc. (MRK)
Looking to acquire marijuana based drug companies.
8. AbbVie Inc. (ABBV)
AbbVie offers drug capsules - Marinol which is part of a class of medications called cannabinoids. Marinol treats nausea and vomiting caused by chemotherapy and restores hunger in AIDS patients.
9. Corbus Pharmaceuticals Holdings Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
10. Cara Therapeutics Inc. (CARA)
Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors.